Keyword: Merck KGaA

The Temasek-led series C round comes five months after Akili posted positive data from a pivotal clinical trial of its digital medicine.

Evobrutinib cut gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say if it beat Tecfidera.

The round sets up the JLABS resident to use advances in synthetic biology to create more targeted, controllable cell and gene therapies.

Syndax is set to put its cocktail through a phase 1b solid tumor trial ahead of midphase trials to demonstrate its safety and efficacy. 

NICE leader joined ABPI; Heptares co-founder will lead Merck’s new London center; Sanofi named a business transformation head.

The pact sets Merck up to work with researchers at CRUK’s unit at the ICR on three preclinical oncology projects.

Roche joins Merck KGaA as pharma parter for Forty Seven's CD47-targeting antibody, which blocks a "don't eat me" signal sent out by malignant cells.

The 510(k) clearance sets Merck up to make the device available to IVF clinics in the first half of next year.

Belgian molecular diagnostics outfit Biocartis says an €80 million private placement will allow it to expand its product range.

Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma.